Methylfenidaat Hcl Retard Viatris (Methylphenidate Hydrochloride)

Methylphenidate works by inhibiting the reuptake of dopamine and norepinephrine in the brain, thereby increasing the levels of these neurotransmitters in the synaptic cleft. The heightened catecholamine activity, especially in the prefrontal cortex, enhances attention, executive function, and wakefulness.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, clinical response, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without altering the regimen on their own.

Safety data for methylphenidate in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case and advise accordingly.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate and amphetamine‑based stimulants share a similar mechanism of increasing dopamine and norepinephrine, but they differ in pharmacokinetics and side‑effect profiles. Methylphenidate generally has a shorter half‑life and may be preferred when a rapid onset or flexible dosing is needed, whereas amphetamines often provide longer‑lasting effects.

Store the product at ambient temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the medication out of reach of children and do not use it after the expiration date printed on the label.

The medication is taken orally, usually as a whole tablet swallowed with water. It should be taken at the prescribed times, often in the morning and early afternoon, to avoid interference with sleep. Patients should not crush, chew, or split extended‑release formulations unless directed by a clinician.

Serious risks include cardiovascular complications such as hypertension or tachycardia, psychiatric events like new or worsening psychosis, and rare but severe allergic reactions. Patients should be monitored for chest pain, severe mood changes, or signs of an allergic response and seek medical attention promptly if they occur.

The drug is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, or patients with serious cardiovascular disorders, uncontrolled hypertension, severe anxiety, or a history of psychosis. A thorough medical evaluation is required before initiating therapy.